touchENDOCRINOLOGY were delighted to speak with Prof. Hiddo Lambers Heerspink to hear more about the highly anticipated results of DAPA-CKD, investigating dapagliflozin in patients with chronic kidney disease with or without type 2 diabetes.
Disclosures: Prof. Lambers Heerspink discloses the following: Grant Funding and Consultancy from AstraZeneca, Boehringer Ingelheim and AbbVie, Steering committee member for Bayer and Chinook, Advisory Board for Mundipharma and Merck, Advisory Board and Speaker for Mitsubishi Tanabe, Steering committee member and Advisory Board for Janssen, Steering committee member for Gilead and CSL Pharma and Consultancy for Retrophin and Novo Nordisk.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the European Association for the Study of Diabetes (EASD) 2020.
